Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. INCY
stocks logo

INCY

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
1.35B
+14.58%
1.908
+33.46%
1.25B
+18.26%
1.641
+41.48%
1.36B
+11.75%
1.925
+22.59%
Estimates Revision
The market is revising Upward the revenue expectations for Incyte Corporation (INCY) for FY2025, with the revenue forecasts being adjusted by 2.77% over the past three months. During the same period, the stock price has changed by 15.95%.
Revenue Estimates for FY2025
Revise Upward
up Image
+2.77%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+13.78%
In Past 3 Month
Stock Price
Go Up
up Image
+15.95%
In Past 3 Month
Wall Street analysts forecast INCY stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for INCY is 95.60 USD with a low forecast of 73.00 USD and a high forecast of 125.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
Wall Street analysts forecast INCY stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for INCY is 95.60 USD with a low forecast of 73.00 USD and a high forecast of 125.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
10 Hold
1 Sell
Moderate Buy
Current: 100.460
sliders
Low
73.00
Averages
95.60
High
125.00
Current: 100.460
sliders
Low
73.00
Averages
95.60
High
125.00
Barclays
NULL -> Overweight
upgrade
$101 -> $115
2025-11-24
Reason
Barclays
Price Target
$101 -> $115
2025-11-24
upgrade
NULL -> Overweight
Reason
Barclays raised the firm's price target on Incyte to $115 from $101 and keeps an Overweight rating on the shares. The firm updated the company's model ahead of data releases in December.
Piper Sandler
Allison Bratzel
Overweight
upgrade
$82 -> $102
2025-11-04
Reason
Piper Sandler
Allison Bratzel
Price Target
$82 -> $102
2025-11-04
upgrade
Overweight
Reason
Piper Sandler analyst Allison Bratzel raised the firm's price target on Incyte to $102 from $82 and keeps an Overweight rating on the shares. The firm notes the company shared strong Q3 results, with Jakafi posting a $20M beat and Opzelura beating consensus by $11M, with non-GAAP EPS of $2.26 representing 63c upside from consensus. Given continued commercial momentum, coupled with key leadership changes, strategic partnerships, and pipeline prioritizations, Piper thinks the risk/reward remains favorable at current levels and remains a buyer.
Wells Fargo
Wells Fargo
Overweight
maintain
$97
2025-11-03
Reason
Wells Fargo
Wells Fargo
Price Target
$97
2025-11-03
maintain
Overweight
Reason
Commenting on the INCB0989 abstract, Wells Fargo says early signs look highly encouraging in myelofibrosis and safety looks good. The firm believes Incyte's shares should trade up on the abstract. Wells thinks the early data cut demonstrates '989 is safe in combination with Jakafi, significant monotherapy treatment activity, while combo data is early but encouraging. Further, it believes '989 will exceed expectations at American Society of Hematology. The firm has an Overweight rating on the shares with a price target of $97.
Guggenheim
Michael Schmidt
Neutral -> Buy
upgrade
$125
2025-11-03
Reason
Guggenheim
Michael Schmidt
Price Target
$125
2025-11-03
upgrade
Neutral -> Buy
Reason
Guggenheim analyst Michael Schmidt upgraded Incyte to Buy from Neutral with a $125 price target.
BofA
Tazeen Ahmad
Buy
maintain
$104 -> $109
2025-10-29
Reason
BofA
Tazeen Ahmad
Price Target
$104 -> $109
2025-10-29
maintain
Buy
Reason
BofA analyst Tazeen Ahmad raised the firm's price target on Incyte to $109 from $104 and keeps a Buy rating on the shares after FY25 revenue guidance was raised following a "strong" Q3 beat. The firm remains "encouraged by the strong performance of the commercial portfolio" and sees several upcoming catalysts for the pipeline, the analyst tells investors.
RBC Capital
Sector Perform
maintain
$81 -> $84
2025-10-29
Reason
RBC Capital
Price Target
$81 -> $84
2025-10-29
maintain
Sector Perform
Reason
RBC Capital raised the firm's price target on Incyte to $84 from $81 and keeps a Sector Perform rating on the shares after its Q3 earnings beat. The company's solid commercial performance for Jakafi and Opzelura, along with newly launched products such as Niktimvo, provided additional tailwinds for a top/bottom line beat, reassuring on its base business, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Incyte Corp (INCY.O) is 13.24, compared to its 5-year average forward P/E of 19.30. For a more detailed relative valuation and DCF analysis to assess Incyte Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
19.30
Current PE
13.24
Overvalued PE
26.96
Undervalued PE
11.63

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
14.67
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
20.73
Undervalued EV/EBITDA
8.62

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.12
Current PS
0.00
Overvalued PS
5.28
Undervalued PS
2.95
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 141.25% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 141.25% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

INCY News & Events

Events Timeline

(ET)
2025-12-01
08:20:00
Incyte Appoints Richard Hoffman as Executive VP and General Counsel Effective Immediately
select
2025-12-01
07:20:00
Guggenheim Initiates Buy Rating on Galecto (GLTO) with $32 Price Target
select
2025-11-18 (ET)
2025-11-18
09:55:01
Significant Early Gainers in Liquid Options on November 18th
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
12-04Newsfilter
Incyte Grants 43,301 Stock Options to New General Counsel Richard Hoffman
  • Inducement Awards: Incyte Corporation has granted 43,301 stock options to Richard Hoffman, the new Executive Vice President and General Counsel, under its 2024 Inducement Stock Incentive Plan, aimed at attracting top executive talent to strengthen leadership.
  • Stock Option Details: The options have an exercise price of $102.04 per share, equal to the closing price on the grant date, with a ten-year term and a vesting schedule that unlocks 25% after one year and the remainder in 36 monthly installments, ensuring continued executive service.
  • Restricted Stock Units: Hoffman also received 9,466 restricted stock units (RSUs), which will vest at 25% on each of the first four anniversaries of the vesting commencement date, further incentivizing his long-term commitment and contributions to the company’s growth.
  • Performance Shares Incentive: Additionally, Hoffman was awarded 23,665 performance shares, which can be earned at 0-200% based on the company's relative total shareholder return over a three-year performance period, motivating a focus on long-term performance and enhancing shareholder value.
[object Object]
Preview
7.5
12-02Newsfilter
Incyte Partners with Winnie Harlow to Raise Vitiligo Awareness
  • Collaborative Awareness: Incyte partners with renowned model Winnie Harlow to enhance public awareness of vitiligo through the 'Power of Choice' campaign, aiming to support the estimated 1.9 to 2.8 million adults in the U.S. affected by the condition.
  • Personal Storytelling: In new videos, Winnie reflects on her childhood experiences with vitiligo, emphasizing the importance of understanding and managing the condition, which encourages patients to choose treatment options that suit their needs and improve their quality of life.
  • Professional Medical Support: Dermatologist Pearl E. Grimes highlights the critical role of patient experiences, as Incyte seeks to provide personalized treatment plans through close collaboration with patients, enabling better management of vitiligo.
  • Brand Influence: Winnie Harlow, celebrated in the fashion industry, has raised $4.1 million for her skincare brand Cay Skin, showcasing her impact on promoting diversity and female empowerment, which further enhances Incyte's brand image in dermatology.
[object Object]
Preview
4.5
11-29TipRanks
Daily Update on SPY ETF for November 28, 2025

  • Market Performance: The SPDR S&P 500 ETF Trust (SPY) rose by 0.55% on Friday, driven by gains in chip stocks, optimism about Federal Reserve interest rate cuts, and increasing energy prices, while the S&P 500 Index and Nasdaq 100 also saw gains.

  • Sector Gains and Outflows: Energy, Consumer Discretionary, and Communication Services sectors performed well, but Healthcare declined; SPY experienced $5 billion in net outflows over the past five days, indicating investor capital withdrawal.

  • Investor Sentiment: Retail sentiment towards SPY remains positive, although hedge fund managers have reduced their holdings in the last quarter; the ETF is rated as a Moderate Buy with a price target suggesting a 15.43% upside potential.

  • Performance Indicators: SPY's Smart Score is seven, indicating expected performance in line with the broader market, and it has five holdings with the highest upside potential alongside five with the greatest downside potential.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Incyte Corp (INCY) stock price today?

The current price of INCY is 100.46 USD — it has decreased -1.02 % in the last trading day.

arrow icon

What is Incyte Corp (INCY)'s business?

Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.

arrow icon

What is the price predicton of INCY Stock?

Wall Street analysts forecast INCY stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for INCY is 95.60 USD with a low forecast of 73.00 USD and a high forecast of 125.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Incyte Corp (INCY)'s revenue for the last quarter?

Incyte Corp revenue for the last quarter amounts to 1.37B USD, increased 20.05 % YoY.

arrow icon

What is Incyte Corp (INCY)'s earnings per share (EPS) for the last quarter?

Incyte Corp. EPS for the last quarter amounts to 2.11 USD, increased 290.74 % YoY.

arrow icon

What changes have occurred in the market's expectations for Incyte Corp (INCY)'s fundamentals?

The market is revising Upward the revenue expectations for Incyte Corporation (INCY) for FY2025, with the revenue forecasts being adjusted by 2.77% over the past three months. During the same period, the stock price has changed by 15.95%.
arrow icon

How many employees does Incyte Corp (INCY). have?

Incyte Corp (INCY) has 2617 emplpoyees as of December 05 2025.

arrow icon

What is Incyte Corp (INCY) market cap?

Today INCY has the market capitalization of 19.72B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free